Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPERIOR: suPAR-guided Meropenem in Sepsis
NCT03717350Phase 3Unknown
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Oct 2018
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of meropenem in sepsis (2 arms), sponsored by Hellenic Institute for the Study of Sepsis. Primary endpoint: Efficacy on early worsening of the patient at 1 day. Status: unknown.
02
Drugs
meropenem
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT03717350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03717350.